PubRank

Claudine Duvivier

Author PubWeight™ 36.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008 2.74
2 Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010 2.15
3 Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009 1.84
4 Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003 1.64
5 Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006 1.63
6 A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009 1.29
7 Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 2012 1.27
8 HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011 1.25
9 Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011 1.06
10 Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011 0.98
11 Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol 2005 0.96
12 Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol 2014 0.96
13 Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004 0.93
14 A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013 0.92
15 Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010 0.91
16 The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010 0.89
17 HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 2007 0.84
18 Skin rash associated with atazanavir: report of three cases. AIDS 2006 0.83
19 Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. AIDS 2002 0.83
20 Pharmacokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant 2003 0.83
21 Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol 2012 0.83
22 Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS 2016 0.83
23 Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008 0.82
24 Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS 2012 0.82
25 Plasma exchange for disseminated cryptococcosis. Am J Kidney Dis 2008 0.80
26 Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial). Antivir Ther 2003 0.78
27 Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther 2005 0.78
28 Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study). J Med Virol 2015 0.77
29 Aortic stiffness aging is influenced by past profound immunodeficiency in HIV-infected individuals: results from the EVAS-HIV (EValuation of Aortic Stiffness in HIV-infected individuals). J Hypertens 2016 0.77
30 TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. AIDS 2008 0.77
31 Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. AIDS 2009 0.77
32 Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level. J Acquir Immune Defic Syndr 2004 0.76
33 Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2006 0.76
34 First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. Medicine (Baltimore) 2016 0.75
35 Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. Medicine (Baltimore) 2016 0.75
36 Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir. Clin Infect Dis 2005 0.75
37 Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. J Antimicrob Chemother 2017 0.75
38 Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr 2009 0.75
39 Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response. AIDS 2014 0.75
40 Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort. Scand J Infect Dis 2011 0.75